Brand Name(s):Bimzelx

Indication:Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy



Review Date:Sep-26

1.1Bimekizumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total Psoriasis Area and the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the company provides the drug according to the commercial arrangement. 1.2 Stop bimekizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as: a 75% reduction in the PASI score (PASI 75) from when treatment started or a 50% reduction in the PASI score (PASI 50) and a 5?point reduction in DLQI from when treatment started.